Category: Guest content

What changes will India’s next Prime Minister bring to India’s Innovative Life Sciences? (Part 2)

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. India’s new Prime Minister  Narendra Modi has asked Ministers to set ambitious targets for the first 100 days of government,. While the BJP Party Manifesto calls for implementation […]


Is the Research Enterprise in Decline? (Part 2)

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. My maiden guest post for the Biotechblog last focused on the global impact of reduced funding for innovative bio-pharma development on clinical research and the threat to the global […]


Biotechnology in Countries Starting with “I” – Part 4: Ireland

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. Perhaps like me you are working and not on vacation this early August.  If so, I hope that you will join me in a mental vacation to the Emerald […]


Crowdsourcing in the Biotech world: Innovation and outreach to a wider public

This guest post is from the BiotechBlog Intern,  Fintan Burke. Fintan is a student at the School of Biotechnology at Dublin City University. Do you have a response to Fintan’s post? Respond in the comments section below. One of the more enduring financing trends in recent years has been to turn to public interest to help […]


Association for Molecular Pathology v Myriad: Attorneys React

This guest post is from the BiotechBlog Intern,  Fintan Burke. Fintan is a student at the School of Biotechnology at Dublin City University. Do you have a response to Fintan’s post? Respond in the comments section below. While the dust has settled on the oral hearings of Association for Molecular Pathology (AMP) v Myriad (read our report […]


After Myriad Oral Argument, Supreme Court Set to Decide Patentability of Isolated Human DNA Molecules

This is a guest post by Morrison & Foerster‘s  Marc A. Hearron, James J. Mullen, III and Matthew I. Kreeger. Do you have a response to this post? Sound off  in the comments section below. The Supreme Court of the United States recently heard oral argument in Association for Molecular Pathology v. Myriad Genetics, Inc. (No. 12-398) to […]


ISO a Scientific Revolution in Cancer Research

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. Even if you have never heard of Thomas Kuhn, your thinking about science has most likely been effected by his theory of what causes paradigm shifts. Over 50 years […]


Will the UK be the Goose that Lays The Golden Access?

This guest post is from the BiotechBlog Intern,  Fintan Burke. Fintan is a student at the School of Biotechnology at Dublin City University. Do you have a response to Fintan’s post? Respond in the comments section below. This month sees the introduction of the UK’s Open Access policy as recommended by the government-commissioned Finch Report into […]


A Long Road to an Informed Public Opinion

This guest post is from the BiotechBlog Intern,  Fintan Burke. Fintan is a student at the School of Biotechnology at Dublin City University. Do you have a response to Fintan’s post? Respond in the comments section below. Bioethics in the public eye has been recognised as an integral part of modern biology research for a while […]


VC Biotech Funding: Perception and Reality

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. VCs are starting to talk again about the ‘perception’ of scarce funding for early stage bio-pharma: At the New Paradigms meeting (a satellite of JPM Conference), a panel I […]